
Weight loss drugs changing way we look at obesity: Dr Ambrish Mithal
Mounjaro and Wegovy have hit the market, and with this the global weight loss revolution has come to India. Dr Ambrish Mithal's book— The Weight Loss Revolution— that's released on Wednesday provides a detailed insight into these weight management drugs and how to use them, in the Indian context. Speaking to HT about the book, Dr Mithal— a renowned endocrinologist— highlights the need for generating awareness among masses about the role of these drugs, who are the right candidates for it, and the side-effects— even though mild— that one is likely to experience. Dr Ambrish Mithal
Does it look like we have reached the stage where no less than a revolution is needed for weight-loss?
Excess weight is a precursor to most modern metabolic disorders but unfortunately the tools to help us lose weight have been very limited. It's been more or less a disaster actually except for extreme cases when you went for surgery, which was utilised by a very small proportion of the population. You really didn't have much by way of drugs that help you lose weight. So, the reason I called it the weight loss revolution was that to address the modern metabolic sort of issues, we need to address weight. And for the first time, this whole crop of drugs that is coming out now, they are changing the way we look at it because they provide us the ability to actually help reduce excess fat and, therefore, reduce all the consequences of excess fat. I think it's a revolution because before this, you were struggling with much lower degrees of weight-loss.
Do you think people still are largely ignorant about the harm that being obese does in terms of health?
Yes, a majority of people look at weight as a cosmetic problem. And even now I am surprised every other day when I explain the relationship between something as obvious as wait and diabetes, many patients are unaware of the association. Even if they do understand the relationship between health and weight, sometimes that is not enough motivation for them to dive deep into obesity. People get motivated much easier by cosmetic issues than health issues.
How is the current class of weight-loss drugs different from its predecessors?
This is the class of drugs called GLP1 drugs, and this class we have been using now for almost two decades. These were developed for treating diabetes, and the initial ones worked very well for diabetes with additional benefits of weight-loss. Research in this area continued— the molecule kept on getting modified— and what made the semaglutide standout was the degree of fat-loss achieved, which was remarkable. It hit 15-16% of the baseline weight that had never been seen before. This is the same class of drugs— GLP1— but the incremental improvements were such that the degree of weight-loss one could achieve was substantially greater. Semaglutide and another molecule called tirzepatide (mounjaro)— a dual GIP and GLP-1 receptor agonist— have crossed the line for us in terms of efficacy and broken the barrier of treating obesity.
What about the side-effects of these drugs?
Anything that has effects will have side-effects. Fortunately, these drugs don't seem to have any sinister long-term side-effects, but yes, tolerability can be an issue with symptoms such as nausea, vomiting, constipation, or diarrhoea that in selected patients— a small proportion— can be troublesome. But these are transient effects. Some other long-term effects related to the eye etc. are still in the realm of research.
Can the weight come back later, if one stops taking these drugs?
In severely obese patients and patients with disorders linked with obesity, it certainly is going to be a life-long therapy. There, however, is a huge chunk of people who are in-between and we don't know yet whether all of them should be on life-long therapy or not. There's likely to be a period of aggressive weight-loss and then a period of weight maintenance that would probably require much lower doses. These drugs need to be a part of weight management programme and not a standalone treatment for obesity. The weight can come back after stopping these drugs, if you haven't tailored your lifestyle significantly.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
an hour ago
- Time of India
Wildlife conservationists conduct drives for students to educate about snakes, alleviate fear
Chhatrapati Sambhajinagar: In an event at MGM school in Padegaon, wildlife conservationists carried out an awareness drive to address fears, curious questions and common misconceptions about snakes to students. "Through an audio-visual presentation, students were introduced to the world of snakes in a scientific and engaging manner. Topics included differences between venomous and non-venomous snakes, behaviour patterns, reasons why snakes sometimes enter human habitats and the importance of snake conservation," said wildlife conservationist Ashish Joshi. Rescue expert Manoj Gaikwad and Chidambar Kale shared real-life examples of snake encounters. The session saw students getting hands-on demonstrations and visual references to help identify various snake species and understand their ecological roles. These drives are conducted in other schools too especially during the rainy season—the motto, replacing fear with knowledge. In another drive, honorary wildlife warden for Chhatrapati Sambhajinagar Dr Kishor Pathak said, "Maharashtra has only four species of venomous snakes, namely Russell's viper, common krait, Indian cobra and Indian saw-scaled viper." "Besides these 'Big Four', we have several species of non-venomous snakes around us that are vital for ecological balance. People often kill snakes of fear, which causes irrevocable damage to nature. They must call rescuers or the forest department for help," he said. Indian rock python, rat snake, kukri, wolf snake, common sand boa, checkered keelback and common trinket snake are among the non-venomous snakes found in the state. "In case of a snake bite, citizens must rush to the nearest hospital. Free anti-venom doses are available at govt hospitals if the bite is from a venomous snake," Pathak said. |


Indian Express
an hour ago
- Indian Express
Smoke-free future: How youth are taking the lead against nicotine addiction
Then just 12 years old, Agamroop Kaur realised that many of her classmates at Canyon Middle School, California, were using e-cigarettes and even noticed a distinct smell in the school bathroom—prompting this young champion to launch an anti-tobacco campaign. Eight years on, the Indian-origin, US-based 20-year-old has not only made an impact but is among the youth ambassadors for the campaign on tobacco-free kids. At the World Conference on Tobacco Control at Dublin, Kaur as a youth ambassador has been engaged actively in various sessions talking about the power of education and advocacy as the driving force to find solutions for the e-cigarette epidemic. As per the WHO Global Tobacco Epidemic Report 2025, there has been a growing trend to regulate the use of e-cigarettes of ENDS – Electronic Nicotine Delivery Systems. The number of countries regulating or banning ENDS has grown from 122 in 2022 to 133 in 2024, a clear signal of increased attention to these products. However over 60 countries till lack any regulations on ENDS. Dr Ruediger Krech, director of Health Promotion, WHO, said while significant strides have been made in protecting people from the harmful effects of tobacco, much more needs to be done. Voices of youth is important in this fight and, according to Kaur, collectively there is a power for greater change. Kaur has not only authored op-ed articles, produced a documentary on youth e-cigarettes epidemic but she has made it a mission to educate peers about the dangers of vaping. She worked persistently on successful campaigns in five California cities and Contra Costa County to end the sale of flavoured e-cigarettes. In 2022, she was presented several awards for being a tireless champion for the right to breathe smoke free air. She received the 2022 Barrie's Fiske National Youth Advocate of the Year and strongly feels that the future of tobacco control is youth powered. Currently pursing a major in Cognitive Science and Global Health at UCLA, Kaur has also served on the Board of Directors for public health NGOs and has spoken on global panels for several organisations including the United Nations, CDC and World Heart Federation. 'We have faced several challenges as the tobacco industry challenged the bill that had proposed a ban on tobacco products. But we persisted and the bill was eventually passed,' Kaur recalled. At the conference at Dublin, among other young ambassadors working on tobacco control and mobilising youth to protect their generation from the harms of tobacco and nicotine addiction include Lisa Lu, who is a senior at Stanford University, studying to be a lawyer and who set up the International Youth Tobacco Control, and Manik Marganamahendra, Executive Director of Indonesia Youth Council for Tactical Challenges who received the 2025 Global Young Ambassador of the Year award. 'The best way to promote education about tobacco and its harmful usage is to reach out to students in a simple and easy to understand format. We need to speak their language so that they feel more involved,' said Manik who began his involvement in tobacco control a decade ago at the University of Indonesia where he led student protests on opposing legislations that favoured the tobacco industry. Lisa, 22, too has a played a key role in advocating for a new law prohibiting the sale of flavoured tobacco products in Los Angeles county. She remembers the time when she travelled to China and conducted a survey of 857 students. Witnessing a culture of teenage smoking she set up the IYTC and expanded the organisation to 60 countries. 'There are several challenges but we need to invest in young voices and lead the fight against tobacco,' she said while Gene Gesite Jr. from Philippines spoke about challenges he faced as he grew up surrounded by friends who found smoking very cool. Now as the coordinator of the Global Youth Voices the focus is getting more organisations onboard to step up the fight against nicotine addiction. Anuradha Mascarenhas is a journalist with The Indian Express and is based in Pune. A senior editor, Anuradha writes on health, research developments in the field of science and environment and takes keen interest in covering women's issues. With a career spanning over 25 years, Anuradha has also led teams and often coordinated the edition. ... Read More
&w=3840&q=100)

First Post
2 hours ago
- First Post
Beyond irregular periods: How AMH+ and other new tests are changing PCOS diagnosis for Indian women
Polycystic Ovary Syndrome is rising among Indian women, especially in urban areas. This article explores its symptoms, diagnostic challenges, and how new tools like the AMH+ test offer accurate, non-invasive early detection—empowering women to manage their reproductive health more effectively and proactively. read more Polycystic Ovary Syndrome (PCOS) has emerged as one of the most prevalent hormonal disorders affecting women of reproductive age. Recent studies, including one published in the Journal of the American Medical Association (JAMA), estimate that PCOS affects between 7.2 per cent to 19.6 per cent of Indian women with higher prevalence seen in urban populations. The condition, characterised by hormonal imbalance and metabolic issues, can lead to a range of symptoms, from irregular periods and weight gain to acne, excessive hair growth and infertility. STORY CONTINUES BELOW THIS AD Firstpost talked to Dr. Rishma Pai, an honorary consultant Gynaecologist at the Lilavati, HN Reliance Hospital and Hinduja Hospitals (Mumbai) to understand the growing burden of PCOS in India, the diagnostic challenges women face and how new tools like the AMH+ test are transforming early detection and management. The Rising Tide of PCOS in India Dr Rishma: Urbanisation, sedentary lifestyles, poor dietary habits, and increasing stress levels have all contributed to the rising prevalence of PCOS in India. Coupled with low awareness and stigma surrounding reproductive health, many women either ignore the signs or seek medical attention too late. PCOS is not just a reproductive issue if left unmanaged, it can increase the risk of type 2 diabetes, cardiovascular disease, and endometrial cancer. The Diagnostic Dilemma Dr Rishma: PCOS is often diagnosed using the Rotterdam criteria, which require at least two of the following three features: irregular or absent periods, signs of high androgen levels (clinically or through lab reports), and polycystic ovaries on ultrasound. However, this process can be prolonged and inconsistent. Many women go undiagnosed for years, which delays treatment and worsens their overall health outcomes. Common Challenges Faced by Women Delayed or missed diagnosis due to lack of awareness Discomfort with transvaginal ultrasounds, especially for unmarried women Mismanagement of symptoms, often treated in isolation (e.g., only acne or only irregular periods) Mental health toll due to chronic stress, infertility struggles, and body image issues Diagnostic Tests Available for PCOS in India While we talk about it, there are a range of diagnostic tests available in India. These include: Ultrasound Scan (Pelvic or Transvaginal Ultrasound) Used to detect the presence of multiple small follicles on the ovaries, which gives the condition its name. Often done on Day 2 or 3 of the menstrual cycle. May not be preferred by or suitable for all women, especially those who are unmarried. Hormone Blood Tests These measure levels of testosterone, LH (Luteinizing Hormone), FSH (Follicle-Stimulating Hormone), and prolactin. Elevated androgens or a high LH:FSH ratio can indicate hormonal imbalance typical of PCOS. Glucose and Insulin Resistance Tests Includes fasting glucose, insulin levels, and HbA1c to check for insulin resistance or prediabetes. Insulin resistance is a common but under-recognized reason behind PCOS. AMH+ Test (Anti-Müllerian Hormone) A simple blood test that measures AMH levels to evaluate ovarian reserve and function. High AMH levels are associated with PCOS as they reflect the increased load of antral follicles. Therefore, AMH+ is an important indicator to identify PCOS. While there are other AMH tests available in India from different manufacturers, the AMH+ test developed by Roche Diagnostics is the first DCGI-approved diagnostic tool for PCOM in aiding the diagnosis of PCOS in India. It is also CE-marked in Europe, reinforcing its global and regulatory credibility. STORY CONTINUES BELOW THIS AD Unlike traditional diagnostic methods like transvaginal ultrasound, which must be timed with the menstrual cycle and can be invasive, AMH+ can be conducted on any day of the cycle, offering a more convenient, accessible, and non-invasive option. It is the most accurate and reliable test available to diagnose PCOS. Thyroid Function Tests and Lipid Profile Thyroid dysfunction and lipid imbalances are commonly associated with PCOS. These tests are crucial in evaluating broader metabolic impacts and ruling out other conditions that mimic PCOS symptoms. Timely and accurate diagnosis is the first step in managing PCOS effectively. With newer diagnostic tools like the AMH+ test, combined with clinical insights and lifestyle guidance, women can take proactive control over their reproductive health.